GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » PB Ratio

Codexis (Codexis) PB Ratio

: 2.26 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), Codexis's share price is $2.80. Codexis's Book Value per Share for the quarter that ended in Dec. 2023 was $1.24. Hence, Codexis's PB Ratio of today is 2.26.

The historical rank and industry rank for Codexis's PB Ratio or its related term are showing as below:

CDXS' s PB Ratio Range Over the Past 10 Years
Min: 0.88   Med: 7.86   Max: 51.46
Current: 2.26

During the past 13 years, Codexis's highest PB Ratio was 51.46. The lowest was 0.88. And the median was 7.86.

CDXS's PB Ratio is ranked better than
52.97% of 1312 companies
in the Biotechnology industry
Industry Median: 2.39 vs CDXS: 2.26

During the past 12 months, Codexis's average Book Value Per Share Growth Rate was -43.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 4.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 14.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Codexis was 73.30% per year. The lowest was -38.50% per year. And the median was -0.75% per year.

Back to Basics: PB Ratio


Codexis PB Ratio Historical Data

The historical data trend for Codexis's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.92 8.25 12.38 2.12 2.46

Codexis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 2.19 1.57 1.44 2.46

Competitive Comparison

For the Biotechnology subindustry, Codexis's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Codexis's PB Ratio distribution charts can be found below:

* The bar in red indicates where Codexis's PB Ratio falls into.



Codexis PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Codexis's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.80/1.239
=2.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Codexis  (NAS:CDXS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Codexis PB Ratio Related Terms

Thank you for viewing the detailed overview of Codexis's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis (Codexis) Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129

Codexis (Codexis) Headlines